Dear WT2 Members, In support of the agenda below, the co-leads will continue discussing the set of pros and cons that have been extracted from the Closed Generics public comment proceeding (https://www.icann.org/resources/pages/closed-generic-2013-02-05-en) These pros and cons are captured here https://docs.google.com/document/d/1s8aGHhcVyZglx72WKslJ5wA-BosVfaGYUjAgyx4n... and also attached as PDF. Best, Steve From: <gnso-newgtld-wg-wt2-bounces@icann.org> on behalf of Michael Flemming <flemming@brightsconsulting.com> Date: Wednesday, April 26, 2017 at 3:51 AM To: "gnso-newgtld-wg-wt2@icann.org" <gnso-newgtld-wg-wt2@icann.org> Subject: [Gnso-newgtld-wg-wt2] Agenda for Meeting at 21 UTC April 27, 2017 Dear All, Apologies as I have not gotten this out sooner. I am currently unable to have easy access to email right now. However, I plan on being there for our upcoming meeting. For this week's meeting, we will be continuing our last discussion of Closed Generics. Last week we went over the con arguments of the public comment as well as exploring what the potential harms are. I use the word potential because the current RA does not allow for Closed Generics, as such we are unable to determine if any of these are actual harm. If someone does have evidence of actual harm, then please bring it up for discussion. However, we will be seeking proposals and ideas for how we can compromise for a way to allow Closed Generics. If you have any thoughts, we would very much appreciate them. Kind regards, Michael Flemming